News
FDA approves Alzheimer’s drug that slowed cognitive decline in clinical trial
Published
1 year agoon
By
New Yorker
MRI image of brain showing area of Alzheimer patient.
Getty Images
The Food and Drug Administration on Friday granted accelerated approval for the Alzheimer’s drug lecanemab, the second treatment from Biogen and its Japanese partner Eisai to receive an early green light in less than two years.
The FDA’s approval comes after clinical trial results published in November indicated that lecanemab slows cognitive decline somewhat in people with mild impairment due to Alzheimer’s disease, but the treatment also carries risks of brain swelling and bleeding.
Eisai, which led the development of lecanemab, is pricing the treatment at $26,500 per year in the U.S. It will be sold under the name Leqembi.
The FDA can accelerate approval of a drug to quickly bring it to market if it’s expected to help patients suffering from serious conditions more than what is currently available. Biogen and Eisai applied for accelerated approval in July.
“Alzheimer’s disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones,” said Dr. Billy Dunn, director of the FDA’s neuroscience division, in a statement. “This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer’s, instead of only treating the symptoms of the disease.”
More than 6.5 million people in the U.S. suffer from Alzheimer’s. The irreversible disease destroys memory, thinking skills, and eventually the ability to carry out simple tasks.
The decision on lecanameb comes after Congress issued a scathing report last week about how the FDA handled the controversial approval of another Alzheimer’s drug developed by Biogen and Eisai, called Aduhelm. The 2021 approval of that treatment, which experts said did not show a clear clinical benefit, was “rife with irregularities,” according to the report.
The congressional report said the “FDA must take swift action to ensure that its processes for reviewing future Alzheimer’s disease treatments do not lead to the same doubts about the integrity of FDA’s review.”
Modestly slows disease
Lecanemab is a monoclonal antibody that targets a protein called amyloid which builds up on the brain in people with Alzheimer’s. The antibody is administered intravenously every two weeks in doses determined by a patient’s body weight with 10 milligrams given per kilogram.
The FDA approved lecanemab based on the reduction of amyloid plaque observed in clinical trial participants who received the treatment, according to a statement from the agency. Participants who did not receive the treatment, the placebo arm, had no reduction in amyloid plaque.
The clinical trial results, published in the New England Journal of Medicine, found that cognitive decline was 27% slower over 18 months in people who received lecanemab compared with those who did not receive the treatment. The study was funded by Biogen and Eisai.
Cognitive decline was measured using a system called the clinical dementia rating, which is an 18-point scale with a higher score indicating a greater level of impairment. It measures cognitive functions such as memory, judgement and problem solving.
Alzheimer’s disease progressed 1.21 points on average in the group that received lecanemab compared with 1.66 points in the group that did not receive the treatment, a modest difference of 0.45 points.
Nearly 1,800 people ages 50 to 90 years old with early Alzheimer’s participated in the trial, about half of whom received lecanemab and half of whom did not.
Safety concerns
Though lecanemab may slow cognitive decline somewhat, the treatment also carries risks.
Nearly 13% of those who received lecanemab developed brain swelling compared with about 2% in the group that didn’t receive the treatment. However, most of these cases were mild to moderate in severity, did not cause symptoms, and typically resolved within four months.
About 3% of patients who received lecanemab had more serious brain swelling with symptoms that included headache, visual disturbance and confusion.
About 17% of those who received lecanemab had brain bleeding, compared with 9% in the group that did not take the treatment. The most common symptoms associated with the bleeding was dizziness.
Overall, 14% of people who received lecanemab suffered serious adverse events in the clinical trial, compared with 11% of those who did not receive the treatment.
The authors of the study said longer clinical trials were needed to determine the efficacy and safety of lecanemab in patients with early Alzheimer’s disease.
The FDA said the prescribing information for lecanemab will include a warning about a risk of swelling and bleeding, broadly referred to as amyloid-related imaging abnormalities.
The death of a clinical trial participant in the Chicago area could also possibly be linked to lecanemab, according to a research letter published in the New England Journal of Medicine this week.
The 65-year-old suffered a stroke and was hospitalized four days after their third lecanemab infusion. A CT scan performed after the patient’s stroke found extensive bleeding in the brain. An MRI performed 81 days before the stroke had not found any bleeding.
The patient had also received a medication, called t-PA, used to break apart blood clots that cause strokes. But extensive brain bleeding would be an unusual complication of this medication alone, according to the physicians who penned the research letter.
Researchers involved in the lecanemab clinical trial, in a response letter, argued that the blood clot medication appeared to be the immediate cause of the patient’s death, with the first symptoms occurring 8 minutes after they received an infusion of the blood-clot buster.
CNBC Health & Science
Read CNBC’s latest global health coverage:
Source: CNBC
A First Look at Samsung’s 2024 TV Lineup
Claims Russian Wagner mercenaries are killing civilians in Mali
FHP trooper who stopped driver from crashing into Skyway 10K runners to fly with Thunderbirds
First Look: Samsung Music Frame
Teflon Tiger Woods has ‘no social skills whatsoever’ and calls humiliated ex-wife his ‘best friend’, despite awkward reunion at son’s golf ceremony: Golf’s greatest star is still oblivious to his scandalous public image at 48
Baltimore Lost More Than a Bridge
King Charles Is ‘Utterly Determined’ to Show Unity Among the Royal Family Amid Health Battles
Living with an anti-reunification North Korea – Asia Times
Los Angeles Theatre Week Provides Access to Affordable Productions
Thousands of phones and routers swept into proxy service, unbeknownst to users
A First Look at Samsung’s 2024 TV Lineup
Kate Middleton Had ‘Very Difficult, Different’ Cancer Conversations With 3 Children Says King Charles’ Former Butler
US debates while China implements Cyber Force concept – Asia Times
‘Murder in progress’: Cohasset police tried to spare attacker’s life as they saved woman from assault
Is a Nintendo Switch Worth Buying Right Now?
Trending
-
Auto22 hours ago
The Kia K4 Hatchback Is Coming to the US
-
Travel24 hours ago
Record-breaking year for NSW as visitor expenditure soars past $50 billion
-
Wellness23 hours ago
Exercise Might Be the Natural Sleep Aid You’re Seriously Overlooking
-
Travel23 hours ago
Melbourne to Hear the Roar of British & Irish Lions in 2025
-
Travel20 hours ago
Hotel development across Africa.
-
Auto22 hours ago
Desperate Fisker Drops Ocean Base Price to $24,999 in an Attempt to Survive
-
Auto16 hours ago
The 670-HP Porsche Panamera Turbo E-Hybrid Costs $192,995
-
Auto23 hours ago
The New Kia K4 Is Bigger Than the Forte and Has Two Engine Options